A domestic pharmaceutical company has joined forces with key local partners to strengthen its dominance in the Southeast Asian market. Korea United Pharm announced that on the 27th it invited representatives from QualiMed, a pharmaceutical distribution company in the Philippines, Indonesia’s Dexa Group, and GDM, Dexa’s Philippine subsidiary, to its headquarters for in-depth strategic discussions aimed at expanding exports.

The meeting was attended by key decision-makers from each company, including Kang Deok-young, CEO of Korea United Pharm; Oscar Aragon, CEO of QualiMed; and Marcus Pite, Director of Dexa Group. They discussed plans to expand the pharmaceutical supply chain in the Philippines and designed mid- to long-term cooperation models to increase the market share of anticancer products.

Immediately after the meeting, the guests visited Korea United Pharm’s second plant, located in Sejong Special Self-Governing City. Partner company representatives toured a dedicated anticancer drug production line equipped with advanced facilities, confirming the level of technology applied across the entire process and thereby reinforcing confidence in the products. This inspection is viewed as an encouraging signal for increasing future export volumes and consolidating the company’s position in the local market.

The Philippine pharmaceutical market is showing rapid growth. As of 2024, the market is valued at approximately USD 6.1 billion (around KRW 9 trillion) and is forecast to expand to about USD 7.5 billion (around KRW 11.006 trillion) by 2029. In particular, demand for anticancer drugs is surging due to the increase in chronic disease patients, while dependence on imports remains high, leading to the assessment that there is significant potential for penetration by high-quality Korean pharmaceuticals.

Cultural exchange activities held prior to the main business discussions also attracted attention. On the 24th, Korea United Pharm hosted a classical music performance at the History Campus in Gwangju, Gyeonggi-do, inviting 26 key Filipino medical professionals and stakeholders. This initiative is interpreted as a move to enhance brand awareness among local expert groups by strengthening emotional ties that go beyond simple business relationships.

Kang Deok-young, CEO of Korea United Pharm, stated, “Based on the trust that has been built over a long period with local partner companies, we will begin full-scale supply of key anticancer products. We will continue aggressive marketing and sales activities to achieve meaningful results in the Philippine pharmaceutical market, which has significant growth potential.”

Starting with this event, Korea United Pharm plans to overhaul its anticancer drug supply system in the Philippines and secure export momentum through customized strategies aligned with local demand.

Popular News